Imunon (IMNN) director granted 6,934 shares of stock for board fees

Rhea-AI Filing Summary

Dentzer James E reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. reported that director James E. Dentzer received a grant of 6,934 shares of common stock on July 31, 2026, as a stock grant in lieu of cash for a portion of his board fees at an indicated value of $1.59 per share. Following this award, he directly holds 21,897 shares of Imunon common stock.

Insider Trade Summary

Net Buyer: 6,934 shares

Net Buy 1 txn

Insider Dentzer James E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	6,934	$1.59	$11K

Holdings After Transaction: Common Stock — 21,897 shares (Direct)

Footnotes (1)

1. F1. Stock granted in lieu of cash for portion of board fees

Key Figures

Shares granted: 6,934 shares Grant price per share: $1.59 per share Shares held after grant: 21,897 shares

3 metrics

Shares granted 6,934 shares Common stock grant to director James E. Dentzer on July 31, 2026

Grant price per share $1.59 per share Implied value used for the 6,934-share stock grant in lieu of cash board fees

Shares held after grant 21,897 shares Total direct Imunon common stock holdings of James E. Dentzer following the transaction

Key Terms

grant, award, or other acquisition, in lieu of cash, board fees, Common Stock

4 terms

grant, award, or other acquisition regulatory

"Transaction code description is "grant, award, or other acquisition" for the shares"

in lieu of cash financial

"Footnote states stock was granted in lieu of cash for board fees"

board fees financial

"Stock granted in lieu of cash for portion of board fees"

Common Stock financial

"Security title for the reported insider transaction is Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 04:17 PM Accepted by SEC EDGAR 08/04/2026 - 04:16 PM Learn about SEC filing dates

FAQ

What insider transaction did Imunon (IMNN) disclose in this Form 4?

Imunon (IMNN) disclosed that director James E. Dentzer received a grant of 6,934 shares of common stock on July 31, 2026. The shares were granted in lieu of cash for a portion of his board fees at $1.59 per share.

How many Imunon (IMNN) shares did James E. Dentzer receive?

Director James E. Dentzer received 6,934 shares of Imunon common stock. According to the filing, this was a stock grant in lieu of cash for part of his board fees, rather than an open-market purchase, and is classified as a grant or award acquisition.

What price per share is associated with the Imunon (IMNN) stock grant to Dentzer?

The reported value for the grant to James E. Dentzer is $1.59 per share. This price is tied to the 6,934-share stock award he received in lieu of cash compensation for a portion of his board service fees on July 31, 2026.

What are James E. Dentzer’s Imunon (IMNN) holdings after this Form 4 transaction?

After the reported stock grant, James E. Dentzer directly holds 21,897 shares of Imunon common stock. This total reflects his position immediately following the 6,934-share award granted in lieu of cash for a portion of his board fees.

Was the Imunon (IMNN) stock transaction for James E. Dentzer an open-market buy or a grant?

The transaction was a grant/award acquisition, not an open-market purchase. The filing states the 6,934 shares of common stock were granted in lieu of cash for part of James E. Dentzer’s board fees, using a value of $1.59 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dentzer James E

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2026		A		6,934(1)	A	$1.59	21,897	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for portion of board fees

	/s/ Susan Eylward, Attorney-in-Fact for James E. Dentzer	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)